全文获取类型
收费全文 | 7215篇 |
免费 | 423篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 174篇 |
妇产科学 | 144篇 |
基础医学 | 1144篇 |
口腔科学 | 144篇 |
临床医学 | 553篇 |
内科学 | 1815篇 |
皮肤病学 | 275篇 |
神经病学 | 622篇 |
特种医学 | 202篇 |
外科学 | 665篇 |
综合类 | 31篇 |
预防医学 | 324篇 |
眼科学 | 169篇 |
药学 | 597篇 |
中国医学 | 24篇 |
肿瘤学 | 716篇 |
出版年
2023年 | 47篇 |
2022年 | 117篇 |
2021年 | 177篇 |
2020年 | 98篇 |
2019年 | 184篇 |
2018年 | 177篇 |
2017年 | 149篇 |
2016年 | 179篇 |
2015年 | 182篇 |
2014年 | 255篇 |
2013年 | 313篇 |
2012年 | 521篇 |
2011年 | 533篇 |
2010年 | 304篇 |
2009年 | 267篇 |
2008年 | 435篇 |
2007年 | 499篇 |
2006年 | 508篇 |
2005年 | 500篇 |
2004年 | 462篇 |
2003年 | 405篇 |
2002年 | 432篇 |
2001年 | 83篇 |
2000年 | 71篇 |
1999年 | 73篇 |
1998年 | 93篇 |
1997年 | 73篇 |
1996年 | 64篇 |
1995年 | 49篇 |
1994年 | 40篇 |
1993年 | 29篇 |
1992年 | 46篇 |
1991年 | 43篇 |
1990年 | 39篇 |
1989年 | 32篇 |
1988年 | 22篇 |
1987年 | 20篇 |
1986年 | 24篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 10篇 |
1981年 | 7篇 |
1979年 | 23篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1974年 | 5篇 |
1972年 | 6篇 |
1968年 | 7篇 |
排序方式: 共有7679条查询结果,搜索用时 15 毫秒
11.
Tsuyoshi Satoh Tadashi Watanabe Masanori Tadokoro Junichi Sakamoto Hiroki Murayama Katsuki Itoh Sadayuki Sakuma Hiroshi Takagi 《Cancer science》1992,83(4):379-386
Anti-carcinoembryonic antigen monoclonal antibody (MAb) CEA102 was produced by immunization with purified CEA and the specific accumulation of radiolabeled CEA102 in colorectal cancers was investigated by autoradiography of surgical specimens using Fuji Computed Radiography (FCR). Five patients with colorectal cancer were injected intravenously with 131 I-labeled intact CEA102 or its F(ab')2 . Primary tumor and liver metastases were successfully detected by external scanning with a gamma camera in 4 cases. Autoradiographic study of the surgical specimens using FCR showed predominant localization of 131 I-labeled CEA102 in primary tumors and liver metastases in all cases. Even a small liver metastasis (0.5 cm) was clearly visualized in the autoradiogram by FCR. The pixel distribution curves of the density of the respective tissues in the autoradiograms by FCR showed the heterogeneity of the distribution of administered radiolabeled MAb in individual tumors, but the density of the tumors was higher than that of the normal tissues. In the quantitative distribution analysis of CEA102, the uptake of the primary tumor (mean 1.10%ID/kg) was ten-fold greater than that of the normal colon mucosa (mean G.10%ID/kg). These results revealed that the application of MAb has great potential in radioimmunodetection as well as in antibody-directed therapy. 相似文献
12.
13.
J Yoshida T Wakabayashi M Mizuno K Sugita H Seo M Oshima M Tadokoro S Sakuma 《Neurologia medico-chirurgica》1992,32(3):125-129
Iodine-131-labeled G-22 monoclonal antibody F(ab')2 fragment reaching specifically with a glioma-associated surface glycoprotein was administered to 12 glioma patients to investigate its use in radioimaging of intracranial gliomas. No immediate or delayed side effects were attributable to antibody injection. Nine patients received the radiolabeled complex intravenously. The images of low-grade gliomas were generally poor and disappeared within 4 days. High-contrast images were obtained beyond the 7th day in high-grade gliomas except one case in the pineal region. Three patients received intraventricular or intratumoral administration. Clear images of all tumors were demonstrated from the 2nd until later than the 7th day. One patient with cerebrospinal fluid (CSF) dissemination of brainstem glioma demonstrated negative CSF cytology after intraventricular administration. 相似文献
14.
Y Uchihashi T Morimoto S Tadokoro 《Nihon yakurigaku zasshi. Folia pharmacologica Japonica》1992,99(3):153-160
Effects of mosapramine (Y-516), a new dopamine D2 antagonist, on reverse tolerance (sensitization) after repeated administration of methamphetamine (MAP; 2 mg/kg, s.c.) were investigated by means of ambulatory activity in mice; and they were compared with those of clocapramine (CCP), bromperidol (BPD) and chlorpromazine (CPZ). Y-516 (0.3, 1, 3 and 10 mg/kg, p.o.), CCP (3, 10 and 30 mg/kg, p.o.), BPD (0.1, 0.3 and 1 mg/kg, p.o.), CPZ (1, 3 and 10 mg/kg, p.o.) or 0.5% methylcellulose (MC; solvent, p.o.) were given to mice 30 min before MAP administration. The ambulatory activity was measured by tilting-type activity changes for 3 hr after MAP. These treatments were repeated 5 times at 3-4 day intervals. Then MAP alone was challenge-administered to all of these mice 3-4 days after the final administration. Marked reverse tolerance was produced after repeated administration of MC plus MAP. On the other hand, the ambulation-increasing effect of MAP was suppressed dose-dependently in groups pretreated with Y-516 or comparison-drugs, although the development of reverse tolerance was not completely inhibited after the repeated administration. In the challenge-administration of MAP, the ambulation-increasing effect was dose-dependently suppressed in the Y-516 group or the comparison-drug plus MAP group as compared with that in the MC plus MAP group. 相似文献
15.
Takuya Watanabe Keiko Takahashi Tomoko Kanome Shigeki Hongo Akira Miyazaki Shinji Koba Takashi Katagiri Rajbabu Pakara Claude R Benedict 《Hypertension research》2006,29(10):821-831
Human urotensin-II (U-II) is the most potent vasoactive peptide identified to date, and may be involved in hypertension and atherosclerosis. We investigated the effects of the interactions between U-II or other vasoactive agents and mildly oxidized low-density lipoprotein (mox-LDL) or hydrogen peroxide (H2O2) on the induction of vascular smooth muscle cell (VSMC) proliferation. Growth-arrested rabbit VSMCs were incubated with vasoactive agents (U-II, endothelin-1, angiotensin-II, serotonin, or thromboxane-A2) in the presence or absence of mox-LDL or H2O2. [3H]Thymidine incorporation into DNA was measured as an index of VSMC proliferation. On interaction with mox-LDL or H2O2, U-II induced the greatest increase in [3H]thymidine incorporation among these vasoactive agents. A low concentration of U-II (10 nmol/l) enhanced the potential mitogenic effect of low concentrations of mox-LDL (120 to 337%) and H2O2 (177 to 226%). U-II at 50 nmol/l showed the maximal mitogenic effect (161%), which was abolished by G protein inactivator (GDP-beta-S), c-Src tyrosine kinase inhibitor (radicicol), protein kinase C (PKC) inhibitor (Ro31-8220), extracellular signal-regulated kinase (ERK) kinase inhibitor (PD98059), or Rho kinase inhibitor (Y27632). Mox-LDL at 5 microg/ml showed the maximal mitogenic effect (211%), which was inhibited by free radical scavenger (catalase), intracellular and extracellular antioxidants (N-acetylcysteine and probucol), nicotinamide adenine dinucleotide phosphate oxidase inhibitor (diphenylene iodonium), or c-Jun N-terminal kinase (JNK) inhibitor (SP600125). These results suggested that U-II acts in synergy with mox-LDL in inducing VSMC DNA synthesis at the highest rate among these vasoactive agents. Activation of the G protein/c-Src/PKC/ERK and Rho kinase pathways by U-II together with the redox-sensitive JNK pathway by mox-LDL may explain the synergistic interaction between these agents. 相似文献
16.
Hiroyoshi Suzuki Taisuke Otsuki Yuzo Iwasaki Ryuichi Katakura Hideshi Asano Mamoru Tadokoro Yoichi Suzuki Fumiaki Tezuka Hidehiro Takei 《Neuropathology》2002,22(1):40-47
The present case report describes a case of ganglioglioma with a distinct sarcomatous component in the left temporal lobe of a 59‐year‐old Japanese man. Neoplastic neuroglial tissue contained both benign and anaplastic glial components with a MIB‐1 labeling index of 0.1% and 12.0%, respectively. Sarcomatous tissue adjacent to the anaplastic glial tissue was dominated by pleomorphic fibroblastic cells with a MIB‐1 labeling index of 10.8%. They were immunoreactive for smooth muscle actin, type IV collagen, and alpha 1 antitrypsin, but not for desmin and CD34. Interestingly, some of the sarcomatous cells were double‐positive for smooth muscle actin and GFAP. The p53 protein had accumulated in the anaplastic astrocytes and sarcomatous cells, but direct DNA sequencing of PCR products failed to detect any mutation in the p53 gene (from exon 4 to exon 10). 相似文献
17.
Shiro Nakaike Takehiro Yamagishi Kazunori Samata Keiko Nishida Kouko Inazuki Tomoko Ichihara Yoshihiro Migita Susumu Otomo Hironaka Aihara Shigeru Tsukagoshi 《Cancer chemotherapy and pharmacology》1989,23(3):135-139
Summary A novel antitumor compound, N--dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]-phenazine-6-carboxamide sodium salt (NC-190) was evaluated for its antitumor activity in experimental murine tumor systems. In the initial studies with P388 leukemia (i.p.-i.p.), NC-190 led to an increase of >200% in life span (ILS), and 75% of the mice were alive on day 30, when the optimal dose (50 mg/kg, days 1–5) was given. Additionally, the compound had significant activities against i.p. inoculated mouse L1210 leukemia, B16 melanoma, M5076 reticulum cell sarcoma, sarcoma 180, mouse hepatoma MH134, and rat Yoshida sarcoma and Yoshida ascites hepatoma AH130. The optimal dose resulted in a >280% ILS with a 30-day survival of 50% in mice with L1210 leukemia (100 mg/kg, days 1–5), a 156% ILS in mice with B16 melanoma (50 mg/kg, days 1–5), a 98% ILS with a 90-day survival of 25% in mice with M5076 reticulum cell sarcoma (25 mg/kg, days 1, 5, 9, and 13), a >300% ILS with a 60-day survival of 50% in mice with sarcoma 180 (50 mg/kg, days 3–10), a 148% ILS with a 60-day survival of 25% in mice with MH134 (25 mg/kg, days 1–5), a 129% ILS with a 60-day survival of 12.5% in rats with Yoshida sarcoma (12.5 mg/kg, day 3–10), and a >161% ILS with a 60-day survival of 50% in rats with AH130 (6.3 mg/kg, days 3–10). In the experiments with s.c. inoculated tumors, NC-190 not only inhibited tumor growth, but also increased the life span of mice with Lewis lung carcinoma or B16 melanoma. The 60-day survivors accounted for 60% and 30% in mice with Lewis lung carcinoma and B16 melanoma, respectively. The compound significantly inhibited the spontaneous lung metastasis of Lewis lung carcinoma by more than 90% when eight daily i.v. injections were given. NC-190 was active by the i.p., s.c., and i.v. routes. Five consecutive daily i.p. doses (days 1–5) were more effective than a single dose (day 1), two doses (days 1 and 5), or three doses (days 1, 5, and 9). NC-190 warrants further study as a potential antineoplastic agent against human neoplasms, as it has a broad spectrum of antitumor activity and inhibits metastasis.Abbreviations
ILS
increase in life span
-
MST
median survival time
-
MMC
mitomycin C
-
ADM
adriamycin
-
CPA
cyclophosphamide
-
5-FU
5-fluorouracil 相似文献
18.
Tomoko Yoshinari Yoshikazu Iwasawa Keiko Miura Ikuko S. Takahashi Takahiro Fukuroda Kunio Suzuki Akira Okura 《Cancer chemotherapy and pharmacology》1989,24(6):367-370
Summary BS compounds, a series of new dihydropyridines, successfully overcame multidrug resistance in P388/ADR cells in vitro. These agents synergistically potentiated the cytotoxicity of Adriamycin to P388/ADR cells at a concentration of 1–2 M, whereas they showed hardly any synergistic effect in the parental cell line (P388/S) at the same concentration. They inhibited the active drug efflux in P388/ADR cells as well as the binding of [G-3H]-vinblastine to membrane vesicles from P388/ADR, which was increased in resistant P388 cells as compared with parental cells. Besides, unlike the activity of clinically used calcium antagonists, the calcium antagonistic activity associated with BS compounds was very weak: their arterial relaxation activity was <21% of that of verapamil. These data suggest that BS compounds specifically overcome multidrug resistance without the serious hypotensive side effects that accompany the use of verapamil orother calcium antagonists. 相似文献
19.
Koichiro Yuji Shigesaburo Miyakoshi Daisuke Kato Yuji Miura Tomohiro Myojo Naoko Murashige Yukiko Kishi Kazuhiro Kobayashi Eiji Kusumi Hiroto Narimatsu Tamae Hamaki Tomoko Matsumura Masahiro Kami Takahiro Fukuda Shigeru Masuo Kazuhiro Masuoka Atsushi Wake Junichi Ueyama Akiko Yoneyama Ko Miyamoto Haruhisa Nagoshi Michio Matsuzaki Shinichi Morinaga Yoshitomo Muto Yoichi Takeue Shuichi Taniguchi 《Biology of blood and marrow transplantation》2005,11(4):314-318
We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2 , melphalan 80 mg/m 2 , and 4 Gy of total body irradiation. The median infused total cell dose was 2.75 x 10(7)/kg (range, 2.3-3.4 x 10(7)/kg). Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched donor. 相似文献